Canada: Food, Drugs, Healthcare, Life Sciences

On June 30, the Patented Medicine Prices Review Board (PMPRB) published new Guidelines for PMPRB Staff (the Guidelines) that will take effect on Jan. 1, 2026.

Le 30 juin, le Conseil d'examen du prix des médicaments brevetés (le « CEPMB ») a publié les Lignes directrices pour le personnel du CEPMB...

A ruling from the Federal Court of Canada has resulted in an appeal of prior government refusals to permit access to psilocybin in connection with psilocybin assisted psychotherapy ("PSAP").

On June 30, the Patented Medicine Prices Review Board (PMPRB) published new Guidelines for PMPRB Staff (the Guidelines) that will take effect on Jan. 1, 2026.

Le 30 juin, le Conseil d'examen du prix des médicaments brevetés (le « CEPMB ») a publié les Lignes directrices pour le personnel du CEPMB...

A ruling from the Federal Court of Canada has resulted in an appeal of prior government refusals to permit access to psilocybin in connection with psilocybin assisted psychotherapy ("PSAP").

Tory Hibbitt co-authors a comprehensive text on Alberta's Health Information Act and how this important legislation is interpreted and applied.

A ruling from the Federal Court of Canada has resulted in an appeal of prior government refusals to permit access to psilocybin in connection with psilocybin assisted psychotherapy ("PSAP").

On July 2, 2025, the Director of Integrated Community Health Services Centres (the "Director") issued a call for applications for new integrated community health services centre...

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.